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Drug Manufacturer Masquerade: Compounding Manufacturers Use a Wide Gap of State 
and Federal Oversight Authority to Evade Mandatory Safety Controls 
By Joyce Crawford 
 
Abstract: 
 Compounding pharmacies mix, combine, or alter drugs that are not otherwise available in 
the commercial market.  This paper discusses the development of the compounding industry, and 
the various state and federal oversight authorities surrounding it.  These entities are a necessary 
part of the healthcare delivery system, especially in hospitals and clinics where compounded 
drugs are needed in greater volume and cannot be produced on-site.  Recently, however, the 
compounding industry has grown rapidly, and the industry controls that preserve safety and 
quality controls are no longer sufficient.  
 In order for the industry to remain a viable option for safe medication to healthcare 
providers, changes need to be made to ensure the quality of the products.  This objective could 
be made from within the industry through management or technology; however, this paper 
discusses how federal and state regulatory agencies can better ensure that no matter what the 
source, the public is supplied only with safe medication.  As discussed later, it became clear that 
regulatory responsibility over this industry between state and federal agencies was not clear.  A 
thorough investigation by Congress has determined that lack of definition and clarification of 
Federal oversight created confusion and agency liability exposure in the compounding 
manufacturer industry.   
The most recent and extreme case occurred in late 2012, when an outbreak of fungal 
meningitis was caused by contaminated vials of methylprednisolone acetate, produced by the 
New England Compounding Center in Framingham, Massachusetts.  The contaminated solution 
was injected into patient’ joints and spine to treat pain, but instead caused 751 infections and 64 
deaths.  In light of this horrific tragedy, the state and federal agencies, along with Congress, have 
investigated and discussed how to prevent this from happening again.   
 The result of this investigation was the exposure of a gap in regulatory authority between 
the state boards of pharmacy that license pharmacies within their state, and the FDA which 
oversees the mass production and distribution of drugs nationally.  This gap allowed facilities to 
operate under a state license, and hide behind state authority, even when there was evidence that 
they were operating more like a manufacturer.   
To close this gap, ensure compliance with safety controls, and prevent another outbreak of 
adverse events, Congress has enacted legislation, the Drug Quality and Security Act, to clarify 
jurisdictional definition, and require specific registration and reporting from compounding 
manufacturers.  This paper discusses the strengths and weaknesses of the Drug Quality and 
Security Act, and what issues remain.
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I. Introduction 
Compounding manufacturing is the mixing or altering of medications to produce a drug not 
readily available in the commercial market.
1
  It is distinguished from large-scale drug 
manufacturing because, under certain circumstances, compounded drugs are not required to 
comply with the New Drug application process, and other labeling and advertising requirements 
through the U.S. Food and Drug Administration (FDA).
2
  Compound drug production is also 
separate from retail pharmacies because these drugs are generally produced before an individual 
prescription is given to a patient, and are produced in large quantities rather than one at a time.
3
 
The FDA regulates large-scale drug manufactures.
4
  States regulate retail pharmacy 
production of drugs.
5
  Compounding facilities fall in the middle ground, and require oversight by 
both the FDA and the State regulatory authorities.  The Drug Quality and Security Act was 
passed on November 27, 2013 and attempts to clarify regulatory authority over drug 
compounding facilities, by allowing those that meet specific criteria to register with the FDA and 
avoid being required to comply with the New Drug application process.
6
  Part II of this paper 
gives details on the horrific 2012 outbreak of fungal meningitis infections that spurred the 
enactment of new legislation relating to compounding manufacturers.  Part III will discuss the 
                                                        
1
 Thompson v. W. States Med. Ctr., 535 U.S. 357, 360-361 (2002). 
2
 Drug Quality and Security Act, Pub. L. No. 113-54, § 503B, available at 
http://beta.congress.gov/113/bills/hr3204/BILLS-113hr3204enr.pdf. 
3
 Ernest Anderson, et al., Outsource Hosp. Sterile Compounding: A New and Safer Era To Come, 
PHARMACY PRACTICE NEWS, Sept. 2013, at 1. 
4
 The Fungal Meningitis Outbreak: Could it have been prevented?: Hearing Before the H. Subcomm. On 
Oversight and Investigations of the H. Comm. on  Energy & Com., 112
th
 Cong. (2012) [hereinafter House 
Nov. 2012 Hearing], available at http://energycommerce.house.gov/hearing/fungal-meningitis-outbreak-
could-it-have-been-prevented, (last visited Dec. 5, 2013). 
5
 Id. 
6
 THE WHITE HOUSE, Statement by the Press Sec’y on H.R. 1848, H.R. 3204, S. 252 (Nov. 27, 2013) 
available at http://www.whitehouse.gov/the-press-office/2013/11/27/statement-press-secretary-hr-1848-
hr-3204-s-252 (last visited 12/5/2013), Drug Quality and Security Act, Pub. L. No. 113-54, § 503B, 
available at http://beta.congress.gov/113/bills/hr3204/BILLS-113hr3204enr.pdf. 
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compounding industry, its history as well as a brief comparison with large-scale pharmaceutical 
manufacturing.  Part IV will explain the statutory and regulatory framework for this industry. 
Part IV will then discuss the judicial interpretations relevant to federal authority, and the state 
role in pharmacy licensing.  Part V will present the position that expanded federal authority is 
nedded to properly oversee this industry and prevent future public safety risks, and the current 
legislation, its strengths and weaknesses, and concerns that must be addressed to ensure it will 
have the desired effect.  
II. Background on the 2012 NECC Outbreak 
In late September 2012, reports spread across the United States about patients falling ill and 
dying from a terrible disease, which was later identified as fungal meningitis.
7
  This avoidable 
tragedy was one of the worst public health crises this nation has ever experienced.
8
  The disease 
was caused by microbial growth inside what was supposed to be a sterile syringe, the result of 
unsterile conditions at the production facility and contamination.
9
  This particular drug was a 
steroid injection, preservative-free methylprednisolone acetate (MPA), which was administered 
to approximately 14,000 patients in 20 states to treat pain.
10
  These shots were given to patients 
with joint and back pain, often associated with arthritis.
11
  Some of these shots contained a 
common mold called Exserohilum rostratum, a human pathogen usually found in soil and on 
                                                        
7
 CENTERS FOR DISEASE CONTROL & PREVENTION, MULTISTATE FUNGAL MENINGITIS OUTBREAK 
INVESTIGATION, http://www.cdc.gov/hai/outbreaks/meningitis.html (last updated Oct. 23, 2013) 
[hereinafter CDC INVESTIGATION]. 
8
 Sabrina Tavernise & Andrew Pollack, FDA Details Contamination at Pharmacy, N.Y. TIMES (Oct. 16, 
2012), available at  http://www.nytimes.com/2012/10/27/health/fda-finds-unsanitary-conditions-at-new-
england-compounding-center.html?_r=0 (last visited Dec. 6, 2013). 
9
 CDC INVESTIGATION, supra note 7. 
10
 Id. 
11
 CENTERS FOR DISEASE CONTROL & PREVENTION, MORBIDITY AND MORTALITY WEEKLY REPORT: 
Multistate Outbreak of Fungal Infection Associated with Injection of Methylprednisolone Acetate Solution 
from a Single Compounding Pharmacy, (Oct. 19, 2012) 
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6141a4.htm?s_cid=mm 
6141a4_w. 
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plants.
12
  This fungus rarely causes disease in humans, but a combination of factors made it 
deadly, including the fact that it was a preservative free vial, and in many of these deadly cases 
was injected directly into the spine, which has limited protection from the body’s immune 
system .
13
  After injection, the infection multiplied and spread through the epidural space, 
through the spinal fluid and eventually damage to the brain caused bleeding and stroke.
14
 
This compounding pharmacy that produced the drugs, the New England Compounding 
Center (or NECC) located in Framingham, Massachusetts, made 17,000 potentially contaminated 
vials of the steroid injection.  The 3,000 remaining unused lots were voluntarily recalled by 
NECC after the link was made to the outbreak.
15
  To date, there are 751 reported cases, and 64 
Americans have died.
16
   
This was not the first time unsafe drugs from compounding pharmacies have injured people, 
though it was by far the worst and most widespread harm.
17
  Even before the NECC outbreak, 
compounding pharmacies have been linked to at least 23 deaths,
18
 and nine major adverse events 
including infections, hospitalizations, loss of eyesight, and death.
19
  The increased use of 
                                                        
12
 CDC INVESTIGATION, supra note 7. 
13
 House Nov. 2012 Hearing, supra note 4, (exchange between Dr. Hamburg and Congressman Burgess 
occurring at 1:30 on the video).  
14
 Tom M. Chiller, et al., Clinical Findings for Fungal Infections Caused by Methylprednisolone 
Injections, NEW ENG. J. MED. (Oct. 24, 2013), available at 
http://www.nejm.org/doi/full/10.1056/NEJMoa1304879#t=articleTop. 
15
 U.S. FOOD AND DRUG ADMIN., MULTISTATE OUTBREAK OF FUNGAL MENINGITIS AND OTHER 
INFECTIONS: CDC AND FDA LABORATORY-CONFIRMED ORGANISMS FROM PRODUCT SAMPLES, (Dec. 
12, 2012) available at http://www.fda.gov/%20Drugs/DrugSafety/FungalMeningitis/default.htm. 
16
 CDC INVESTIGATION, supra note 7. 
17
 OFFICE OF CONGRESSMAN EDWARD J. MARKEY, STATE OF DISARRAY: HOW STATES’ INABILITY TO 
OVERSEE COMPOUNDING PHARMACIES PUTS PUBLIC HEALTH AT RISK, (2013) [hereinafter STATE OF 
DISARRAY], available at http://www.scribd.com/doc/136535463/State-of-Disarray-Compounding-4-15-
2013 (last visited  Dec. 5, 2013). 
18
 Id. 
19
 Pharm. Compounding: Proposed Legislative Solution: Hearing Before the S. Comm. on Health, Educ., 
Labor & Pensions, 113
th
 Cong. (2013) [hereinafter Senate May 2013 Hearing], available at 
http://www.help.senate.gov/hearings/hearing/?id=f9b68c5e-5056-a032-52b6-4e632afd726a (last visited 
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compounded drugs has developed a robust industry that provides a necessary supply of drugs 
that are not readily available on the retail market.
20
   The compounding industry has grown faster 
than the laws that regulate it, and gaps in the regulatory system have surfaced.
21
  This lack of 
uniform nationwide oversight has only added to the inability of state and federal authorities to 
perform inspections and monitor these laboratories for safety.
22
   Drug manufacturers are 
required by the Federal Food, Drug, and Cosmetic Act to provide sufficient proof of safety and 
efficacy for their products.
23
  However, compounding pharmacies are not required to submit a 
New Drug Application (NDA) before making drugs, so there is no similar approval and 
oversight process.
24
 
Since the deadly fungal meningitis outbreak, the problem of inconsistent and confusing 
regulatory authority persists.  With a combination of poor communication between state and 
federal agencies, and bad actors like NECC, the likelihood of another similar public health crisis 
is almost certain.
25
  The solution to prevent this from happening again is to expand federal 
authority over certain types of compounding pharmacies to bridge the regulatory gaps, together 
with vigorous enforcement of the authority state and federal agencies already possess.   
III. The Compounding Industry & Oversight Mechanisms 
A. Compounding distinguished from traditional drug manufacturing 
                                                                                                                                                                                  
Dec. 5, 2013), STATEMENT OF JANET WOODCOCK, DIR. OF THE FDA CENTER FOR DRUG EVAL. AND 
RESEARCH, 2-3 (May 9, 2013) available at http://www.help.senate.gov/imo/media/doc/Woodcock2.pdf.  
20
 House Nov. 2012 Hearing, supra note 4 (testimony of Hon. Margaret Hamburg, Comm’r of Food and 
Drugs). 
21
 Senate May 2013 Hearing, supra note 19. 
22
 Id. (statement of Dr. Lauren Smith Interim Comm’r of the MA Dep’t of Health). 
23
 21 U.S.C. § 355 (2012).  
24
 21 U.S.C. § 353a (2012).  
25
 House Nov. 2012 Hearing, supra note 4 (testimony of Dr. Hamburg “it’s not a question of if but 
when”). 
 6 
If you place the two entities, large manufacturers and local pharmacists, on a spectrum of 
drug producing businesses, compounding pharmacies would fall somewhere in the middle.  It is 
important to distinguish large-scale commercial drug manufacturing, from compounding, and 
discuss their respective roles in the provision of drugs to the healthcare system.  Traditional 
compounding is the transformation by combining, altering, grinding, or mixing a custom 
medication that is not otherwise widely available.
26
  This is often necessary for pediatric and 
geriatric care, where dosage needs to be adjusted, or for a patient who is allergic to a component 
of the drug.
27
   Traditional compounding also includes suspending a drug in liquid, or adding a 
more appealing flavor to orally administered solutions.
28
   
Traditional compounding is generally performed by, or under the supervision of, a 
pharmacist, and historically at either a local retail pharmacy or on-site at a hospital or clinic.
29
  
Compounding is an integral part of delivering quality healthcare, and the traditional type of one-
person one-prescription drug production has traditionally been regulated by state licensing and 
oversight authorities.
30
   Compounding can be done for non-sterile medications, such as creams, 
ointments or gels applied to skin, or pills and capsules taken by mouth.
31
  Non-sterile drugs have 
a lower-risk of complications or adverse reactions and generally are subject to less regulatory 
scrutiny.
32
  Sterile preparations are usually drugs injected or infused, such as a shot or an IV drip 
                                                        
26
 Thompson v. W. States Med. Ctr., 535 U.S. 357, 360-361 (2002). 
27
 Id. at 361. 
28
 Id. 
29
 U.S. FOOD & DRUG ADMIN., COMPLIANCE POLICY GUIDE § 460.200 (2002) available at 
http://www.fda.gov/ICECI/ComplianceManuals/CompliancePolicyGuidanceManual/ucm074398.htm. 
30
 Id., U.S. FOOD & DRUG ADMIN., COMPLIANCE POLICY GUIDE 7132.16, MANUFACTURE DISTRIBUTION 
AND PROMOTION OF ADULTERATED MISBRANDED, OR UNAPPROVED NEW DRUGS FOR HUMAN USE BY 
STATE-LICENSED PHARMACIES, MAR. 16, 1992. 
31
 U.S. PHARMACOPEIA, USP 36-NF 31: THE OFFICIAL COMPENDIA OF STANDARDS, Section 795, Pharm. 
Compounding: Nonsterile preparations, (2013-2014 ed. 2012). 
32
 Id. (There are still significant risks associated with non-sterile preparations, especially potency and 
purity.) 
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that carry a much higher risk for the spread of infection.
33
  According to proper formulary 
guidelines, the MPA steroid drugs that caused the fungal meningitis, from NECC were supposed 
to be a sterile preparation.
34
 
For certain drugs, for example the electrolytes used in IVs, manufacturers do not distribute 
them in one-dose units.
35
  They are shipped in bulk concentrated form and need to be diluted and 
repackaged for use.
36
  Historically, the doctor, nurse or pharmacist would make the compound 
sterile products (CSPs) on-site, even bedside, before administering the drug to the patient.
37
  As 
hospitals and health systems have grown, the demand for compounded drugs grew; it became 
more efficient for the hospital or clinic to outsource the production of these drugs, rather than 
producing them on-site.
38
  These compounding facilities located off-site, are also known as 
“outsource compounders”, or “outsource facilities”, and are also useful for hospitals when drugs 
are in short supply.
39
 
This should be contrasted against the large-scale drug manufacturing that big pharmaceutical 
companies perform.  This type of manufacturing has been highly regulated because it presents 
more potential safety risks to patients.
40
  Drugs that are mass-produced are not for a specific 
patient who already has a prescription; they are shipped all over the country, and often stored for 
                                                        
33
 U.S. PHARMACOPEIA, USP 36-NF 31: THE OFFICIAL COMPENDIA OF STANDARDS, Section 797, 795: 
Pharm. Compounding: Sterile preparations, (2013-2014 ed. 2012). 
34
 Id. 
35
 Jaimy Lee & Paul Barr, Taking the risk: Despite meningitis outbreak, some hosp. have little choice but 
to rely on compounding pharmacies, MODERN HEALTHCARE (Oct. 13, 2012) 
www.modernhealthcare.com/article/20121013/MAGAZINE/310139991. 
36
 Id. 
37
 Ernest Anderson, et al., Outsource Hosp. Sterile Compounding: A New and Safer Era To Come, 
PHARMACY PRACTICE NEWS, Sept. 2013, at 1. 
38
 Id. 
39
 Senate May 2013 Hearing, supra note 19. 
40
 U.S. FOOD AND DRUG ADMIN., FACTS ABOUT CURRENT GOOD MFG. PRACTICES (CGMPS), (May 2, 
2013) available at 
http://www.fda.gov/drugs/developmentapprovalprocess/manufacturing/ucm169105.htm (last visited Dec. 
5, 2013). 
 8 
a period of time before being sold.  This distribution across state lines and with a longer shelf 
life, warrants heightened scrutiny, and is overseen by the federal government to ensure that 
companies follow what the FDA calls “Current Good Manufacturing Practices.”41 
B. Federal Authority 
a. Federal Statutory Authority 
The Food and Drug Administration (FDA), is the United States’ national agency that 
regulates, among other things, drugs, vaccines and biologics.
42
 The FDA is governed by the Food 
Drug & Cosmetic Act (FDCA), and its subsequent amendments, as well as Title 21 of the Code 
of Federal Regulations.  The FDA is responsible for ensuring the safety and efficacy of drugs, 
through its pre- and post-market review and approval process.
43
    
The FDCA itself was born out of the political response to a deadly high-volume compound 
drug.   In 1937, Sulfanilamide was widely used as a safe treatment for streptococcal infections, 
and when the need for a liquid form arose, a pharmacy in Tennessee compounded 633 shipments 
and sent them out for use.
44
  The mixture proved deadly for over 100 people, and the resulting 
public outcry bolstered the political support for the 1938 Federal Food, Drug, and Cosmetic Act 
                                                        
41
 See generally FDA Current Good Mfg. Practices Rule, 21 C.F.R. § 210.1, 211.1-211.208 (2013). 
42
 U.S. FOOD AND DRUG ADMIN., FDA FUNDAMENTALS, (May 6, 2013) 
http://www.fda.gov/AboutFDA/Transparency/Basics/ucm192695.htm. (last visited Dec. 5, 2013). 
43
 21 U.S.C. §§ 301-450 (2012), (“no person shall introduce or deliver for introduction into interstate 
commerce any new drug, unless an approval of an application filed [with the FDA] . . . is effective with 
respect to such drug." 21 U.S.C. § 355(a)). 
44
 CAROL BALLENTINE, FDA CONSUMER MAGAZINE, TASTE OF RASPBERRIES, TASTE OF DEATH: THE 
1937 ELIXER SULFANILAMIDE INCIDENT (June 1981 Issue), available at 
http://www.fda.gov/AboutFDA/WhatWeDo/History/ProductRegulation/SulfanilamideDisaster/) (last 
updated Oct. 7, 2010). 
 9 
(1938 FDCA).
45
  The 1938 FDCA and subsequent amendments in 1962, have refined the FDA 
authority over manufacturers and “new drugs”.46   
Pharmaceutical companies that research and develop compounds, must seek approval for 
testing from the FDA, and subsequently submit the results of these extensive trials to the FDA 
for New Drug approval.
47
  The FDA, in the interest of drug integrity and quality, has continued 
authority to monitor these registered manufacturers to inspect facilities, and review documents 
and records.
48
 The FDA defines a “new drug” as; 
“Any drug, the composition of which…is not generally recognized, among experts 
qualified by scientific training and experience to evaluate…the drug, as safe and effective 
for use under the conditions prescribed, recommended, or suggested in the labeling 
thereof, except [older drugs designated to be “grandfathered” in].49 
 
Under this broad definition, arguably, each individual compounded drug is a “new drug”.  As 
such, each would require a NDA, or an Abbreviated New Drug Application (ANDA) with the 
FDA before sale and marketing in the United States.
50
  This literal interpretation of “new drug” 
would require each compounded drug to prove with sufficient evidence that it is safe and 
effective for use; this process would be a huge burden to the compounding industry.
51
  The 
                                                        
45
 Wallace F. Janssen, FDA Consumer Magazine, The Story of the Laws Behind the Labels (June 1981 
Issue), available at http://www.fda.gov/AboutFDA/WhatWeDo/History/Overviews/ucm056044.htm) 
(last updated Dec. 14, 2011). 
46
 21 U.S.C. § 321(p)(1) (2012). 
47
 U.S. FOOD AND DRUG ADMIN., NEW DRUG APPLICATION (NDA), available at 
http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalappl
ications/newdrugapplicationnda/default.htm (last updated Feb. 21, 2013). 
48
 21 U.S.C. § 321(p) (20120), (The FDCA authorizes the FDA with the power to enforce its requirements 
in 21 U.S.C. § 371(a)). 
49
 Med. Ctr. Pharmacy v. Mukasey, 536 F.3d 383, 395 (5
th
 Cir. 2008) 
50
 Jesse M. Boodoo, Compounding Problems and Compounding Confusion: Fed. Regulation of 
Compounded Drug Products and the THE FDAMA Circuit Split, 36 AM. J.L. & MED. 220, 230-31 
(2010) 
51
 Id. (“It would be neither practical nor plausible for pharmacists to study individualized compounds in 
clinical trials or prepare NDAs for the near infinite variety of possible compounds that might be 
prescribed.” Id.). 
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FDCA grants the FDA discretionary authority, not to prosecute for “minor violations” of the 
Act.
52
 
The FDA has defined “manufacturer” as; “a person who manufactures a drug…or who is 
licensed by such person to distribute or market the drug…”53, and as “the person who performs 
the…operations required to produce the product: (1) mixing, …(9) sterilizing, and (10) filling 
sterile…drugs into dispensing containers.”54  However, within the statutes and regulations, there 
is no line defining or distinguishing a retail manufacturer from a compounding pharmacy.  There 
is no clear language that states that pharmacies are exempt from jurisdiction under the FDA’s 
authority.  It is conceivable that these two types of businesses could overlap, where a pharmacy 
operates in a manner that qualifies them as a manufacturer.  The laws do make clear that, if the 
moniker “manufacturer” applies, many requirements attach.  These requirements include the 
NDA or ANDA, particular labeling, Good Manufacturing Practices (GMPs), advertising 
restrictions, etc.
55
   
Over a decade ago, in 1992, the FDA raised concerns that state-licensed pharmacists were 
using compounding as a shield to avoid the FDA process for manufacturing.
56
  In response, the 
FDA issued its first compounding Compliance Policy Guide (1992 CPG), which stated that 
compounding pharmacies were not explicitly exempt from FDA authority, but that the FDA 
would generally defer to state authorities and not target traditional retail pharmacies for 
compounding.
57
  In 1997, Congress passed the Food and Drug Administration Modernization 
                                                        
52
 21 U.S.C. § 336 (2012). 
53
 21 C.F.R. § 99.3(f) (2013). 
54
 21 C.F.R. § 201.1(d) (2013). 
55
 21 U.S.C. § 321 (2012). 
56
 U.S. FOOD & DRUG ADMIN., COMPLIANCE POLICY GUIDE § 460.200 (2002) available at 
http://www.fda.gov/ICECI/ComplianceManuals/CompliancePolicyGuidanceManual/ucm074398.htm 
(last updated Jan. 20, 2010).  
57
 Id. 
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Act (FDAMA), which incorporated many of the policies laid out in the 1992 CPG, and brought 
compounding pharmacies within the scope of FDA authority.
58
   
The FDAMA exempted traditional compounding at retail pharmacies from the NDA 
requirements, so long as the drugs were for individual patients with a valid prescription, made 
using only approved ingredients, under endorsed standard manufacturing processes, and not 
“essentially copies” of a commercially available drug.59  This exemption from federal regulation 
would only apply in states that entered a Memorandum of Understanding (MOU) with the 
Department of Health and Human Services.
60
  This MOU gave specific procedures for the way 
state regulators were expected to conduct investigations and respond to complaints about 
compounding pharmacies that were shipping products outside the state.
61
  In states that did not 
enter the MOU, the exemption would only apply to small compounding pharmacies that shipped 
less than 5% of sales across state lines.
62
  FDAMA Section 503A forbade compounders from 
compounding drugs that have been withdrawn from the market for safety reasons.
63
   
The FDAMA’s most controversial provision, 503A(b)(3)(c), forbade compounders from 
advertising or promoting their drugs.
64
   Drug compounding companies quickly challenged the 
FDAMA in court.  This paper will discuss this challenge more fully in the next section, but from 
the start, the line between state and federal jurisdiction to regulate compounding pharmacies was 
unclear.  The FDA updated its guidance document on compounding pharmacies in 2002 (2002 
CPG), which stated the FDA will exercise enforcement discretion if a compounding pharmacy 
                                                        
58
 Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105-115, § 127, 111 Stat. 2296 
(1997) (codified at 21 U.S.C. § 353a (2012)). 
59
 21 U.S.C. § 353a (2012). 
60
 Id. 
61
 Id. 
62
 21 U.S.C. § 353a(b)(3) (2012). 
63
 21 C.F.R. § 216.24 (2013). 
64
 21 U.S.C. §353a(c) (2012). 
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was found to have engaged in any of nine explicit activities, but would otherwise defer to state 
regulatory authorities.
65
  These nine activities relate to the scale of operations and the safety of 
the drugs the pharmacy works with, specifically; 
1. Compounding of drugs in anticipation of receiving prescriptions, except in very limited 
quantities in relation to the amounts of drugs compounded after receiving valid 
prescriptions. 
2. Compounding drugs that were withdrawn or removed from the market for safety 
reasons… 
3. Compounding finished drugs from bulk active ingredients that are not components of 
FDA approved drugs without an FDA sanctioned investigational new drug application 
(IND)… 
4. Receiving, storing, or using drug substances without first obtaining written assurance 
from the supplier that each lot of the drug substance has been made in an FDA-
registered facility. 
5. Receiving, storing, or using drug components not guaranteed or otherwise determined 
to meet official compendia requirements. 
6. Using commercial scale manufacturing or testing equipment for compounding drug 
products. 
7. Compounding drugs for third parties who resell to individual patients or offering 
compounded drug products at wholesale to other state licensed persons or commercial 
entities for resale. 
8. Compounding drug products that are commercially available in the marketplace or that 
are essentially copies of commercially available FDA-approved drug products… 
(except where “appropriate”, or if there is a drug shortage) 
9. Failing to operate in conformance with applicable state law regulating the practice of 
pharmacy.
66
 
 
Unfortunately, without bright, clear and defined lines of binding jurisdiction of authority and a 
strategy for state and federal communication about violations, investigation procedures and 
safeguards broke down.    
b. Judicial Interpretations of Federal Statutes 
In 1999, a group of compounding pharmacies, supported by their trade association the 
International Academy of Compounding Pharmacists (IACP)
67
, challenged the FDAMA Section 
                                                        
65
 U.S. FOOD & DRUG ADMIN., COMPLIANCE POLICY GUIDE § 460.200 (2002) available at 
http://www.fda.gov/ICECI/ComplianceManuals/CompliancePolicyGuidanceManual/ucm074398.htm 
(last updated Jan. 20, 2010).  
66
 Id.  
67
 OFFICE OF CONGRESSMAN EDWARD J. MARKEY, COMPOUNDING PHARMACIES COMPOUNDING RISK 2 
(2012), available at http://interactive.snm.org/docs/Compounding%20Pharmacies%20-
 13 
503A on First Amendment free speech grounds in the Federal District Court in Nevada.
68
  This 
case was later appealed to the Ninth Circuit.
69
  The pharmacies argued that it was 
unconstitutional for the government to prevent these companies from advertising and promoting 
their products, because it restricted their right to commercial free speech.
70
  The District Court 
and Federal Appeals Court held that the restriction was not permissible.
71
  Since this regulation 
was only one of many in the FDAMA amendments pertaining to compounding pharmacies, the 
court also had to determine whether this provision was severable, or whether the whole Section 
503A of the FDAMA had to be struck down.
72
  The Ninth Circuit ultimately determined that 
Congress would not have passed this law without the advertising language, therefore it was not 
severable, and all of the FDAMA §503A was invalid.
73
  However, this holding is only binding in 
the Ninth Circuit.
74
   
The Supreme Court granted review of that decision.
75
  Neither party appealed the issue of 
severability, so the Supreme Court only addressed the constitutionality of the commercial speech 
restriction.
76
  In Thompson v. Western States Medical Center, the Supreme Court upheld the 
Ninth Circuits holding that the FDAMA Section 503A provision prohibiting compounding 
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pharmacies from advertising was an unconstitutional restriction on commercial speech.
77
  
Unfortunately for the FDA, this left the agency and its legal team unclear of what authority they 
had outside of the Ninth Circuit over compounding pharmacies.  In response, the FDA revised 
the 1992 CGP and published the updated Compliance Policy Guide (2002 CPG), as discussed 
earlier in Part II B.   
In 2008, the Fifth Circuit held the opposite of the Ninth Circuit on the severability issue.
78
  
The Fifth Circuit found that though the restriction on commercial speech was unconstitutional, 
the provision was severable and therefore the rest of §503A stands.
79
  In light of this patchwork 
of applicable legal framework, the FDA reaffirmed its previous statement from the 2002 CPG, 
that the FDA would treat all of Section 503A was invalid, except in the Fifth Circuit.  Outside of 
the Fifth Circuit the FDA would continue to operate under its Compliance Policy Guide to 
regulate compounding pharmacies.
80
  This Guidance document however, in its first sentence 
acknowledges that it is not binding; it is not law.
81
  Though it will not have the effect of law in 
court, courts will grant the agency deference to its policy and interpretations.
82
 
                                                        
77
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78
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A 2004 case helps further demonstrate the line between compounding at a retail pharmacy 
and a compounding manufacturer, and is an example of where a court granted the FDA 2002 
CPG guidelines deference.  The FDA was brought to court in 2004 after it tried to inspect 
Wedgewood Pharmacy, a compounding pharmacy in New Jersey.
83
   The FDA had evidence that 
Wedgewood was acting more like a manufacturer, so the FDA agent in charge applied for an 
administrative warrant, which was granted by a magistrate giving access to the facility and 
distribution records.
84
 In the application for the administrative warrant, the FDA pointed to 
specific evidence that Wedgewood was operating as a manufacturer.  The evidence included:   
“in early 1998, Wedgewood had shipped over 1,000 vials of Poison Ivy Extract without 
receiving the requisite prescriptions for specific patients; in May 2002, Wedgewood had 
acquired an encapsulation machine which could be used for large-scale drug 
manufacturing; in 2001 and 2002, it had purchased bulk quantities of substances in 
excess of the amounts normally associated with a retail pharmacy, including enough 
diazepam (the active ingredient in Valium) to manufacture over one million 10 mg doses 
during a six-month period, an amount "typical of a commercial drug manufacturer"; and 
it routinely produced veterinary drugs in bulk, without receiving specific veterinary 
prescriptions.”85 
  
This provides an example of what tangible and real actions the FDA considers in defining how a 
retail manufacturer operates.  The administrative warrant would allow the FDA to assess whether 
Wedgewood’s production was consistent with the actions of a manufacturer, and if so determine 
if there were violations of the FDCA.
86
   
Wedgewood argued that it was exempt from authority 21 USCS § 374(a)(2)(A), which grants 
FDA authority general inspection rights.  The Third Circuit Court of Appeals held that the 2002 
CPG should be granted deference, and because there was evidence that Wedgewood was acting 
as a manufacturer, the FDA was therefore not only entitled to inspection of facilities, but also to 
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inspect records and distribution documents.
87
  This holding was a win for the FDA.  However, 
the FDA was cognizant that moving forward, short of having evidence to support probable cause 
for an administrative warrant, there would be continued push-back from compound pharmacies 
to allow entry for inspection or access to records. The FDA wanted to avoid further litigation 
over what authority it had over compounding pharmacies and became extremely risk averse.
88
  
At this point, the FDA precariously relied on the states to strictly regulate within their borders, 
and identify those pharmacies that were operating outside the scope of their state pharmacy 
license.
89
 
C. State Authority  
Historically, States have had jurisdiction to license and regulate pharmacies that distribute 
drugs to individuals based on prescriptions from physicians.
90
  Each state has their own 
pharmacy regulations, generally administered by a board of pharmacy, which vary in 
registration, fee and oversight requirements.
91
  Typically state boards of pharmacy (hereinafter 
“SBOP”) investigate local pharmacies for offences such as billing violations, or failure to have a 
licensed pharmacist on site, or the unlawful distribution of controlled substances.
92
   
                                                        
87
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88
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Under the current laws, compounding pharmacies are primarily governed by the SBOP of the 
state they operate in, and at the state level there is inconsistency of industry standards.
93
 Each 
state grants the SBOP authority to license and regulate the pharmacies operating within that 
state.  The SBOPs determine the frequency of facility investigations and how they are 
conducted.
94
  Some states conduct routine in-person inspections, some are announced, other 
states rely on pharmacy self-inspections, or only inspect in response to complaints about the 
pharmacy.
95
  Some states have adopted standards developed by the United States Pharmacopoeia 
(USP), an independent non-profit that sets quality, purity, and strength standards for foods and 
medicines.
96
  Twenty-seven states have incorporated USP Section 795, which addresses Non-
Sterile Compounding, and Section 797 for Sterile Compounding Preparation into their pharmacy 
regulations.
97
  The remaining states have developed their own standards, which may not be as 
stringent.  Some states permit non patient-specific compounding in certain narrow situations.
98
    
SBOP are responsible for the pharmacists operating within their jurisdiction, however if 
drugs are compounded and shipped over state lines, the compounding pharmacy is required to be 
licensed in multiple states.
99
   Again, these states may have different levels of safety 
requirements, and inspection standards, and the pharmacy’s home state must ensure that quality 
and process controls are in effect.
100
  
IV. Political Aftermath of the NECC Outbreak 
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A. NECC violations through the regulatory lens 
Now, that a tragedy has occurred and been widely publicized, the FDA and the state of 
Massachusetts have expressed deep regret for not acting sooner on the warning signs for NECC, 
and for a failure to provide regulatory clarity.
101
  The problem is that even with solid and 
unambiguous rules, there may still be bad actors like NECC. 
 The NECC was allegedly using generated patient lists from clinics regardless if those 
patients had prescriptions, as their record of “individual patients” for whom their drugs were 
being produced.
102
  The Massachusetts Dept. of Public Health noted that NECC had shipped out 
two of the later-recalled lots of contaminated MPA before the results of sterility testing had been 
received.
103
  The FDA investigation inspection following the outbreak found there was mold 
growing on surfaces that were supposed to be sterile, and an air conditioning unit intended to 
stabilize air temperature and humidity was turned off at night, though it was supposed to run 
continuously.
104
  The FDA form 483 issued following the facility inspection stated that vials of 
MPA from one of the suspect lots had “greenish black foreign matter” in the solution.105 
The NECC was a licensed pharmacy by the Commonwealth of Massachusetts, but had been 
flagged by the state and federal authorities multiple times in the past before the meningitis 
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outbreak for violations.
106
  In 2002, the FDA was alerted to two cases of symptoms of bacterial 
meningitis linked to NECC for the same drug, MPA, which led to FDA and state facility 
investigations.
107
  The Massachusetts SBOP issued three “non-disciplinary private advisory 
letters” to the NECC in 2004, after complaints came from South Dakota, Texas and Wisconsin 
that the NECC was soliciting bulk orders rather than patient specific prescriptions.
108
  In 2006, as 
part of a consent decree for past violations, the NECC submitted to an FDA and SBOP 
inspection, which turned up 189 vials of a commercially available product “Trypan Blue.”109  
This discovery led to an FDA Warning Letter sent to the NECC, generally the last step before 
enforcement action, but further action was never taken.
110
  
The state failed to take action, and subsequently the state agency’s administration has been 
placed under new management.
111
  The FDA was tentative to take enforcement action because of 
a “patchwork quilt”112 of jurisdiction that arose out of the court challenges to the FDAMA 
amendments.  The Circuit Court split led to two different legal frameworks being applied in 
certain states, and other states left guessing what law applied to them.  If the compounding 
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pharmacy followed the requirements of the state and federal government, or even their own 
standard operating procedures to keep their laboratory and clean room up to code, this likely 
would never have happened.
113
  This was not just the failure of NECC to maintain high quality 
and safety standards, but also a failure of the federal and state authorities from taking more 
aggressive action after repeated reports of violations and unsafe products.
114
 
B. Federal and state investigation on how to address the regulatory gap. 
In April 2013, the FDA issued a report that it had amplified its enforcement and regulation of 
sterile drug compounding pharmacies.
115
  Though still asserting that it lacks sufficient authority, 
the FDA conducted 31 total inspections, three with additional administrative warrants because of 
refusal to cooperate by the compounding pharmacy.
116
  The FDA identified these compounding 
pharmacies based on a risk assessment, considering the type of drugs being compounded, 
distribution, as well as previous reports from states on allegations of violations.
117
  Almost all of 
these inspections were conducted in coordination with the respective SBOP regulators.
118
  The 
FDA found violations and subsequently issued Form 483s, an official document detailing the 
violations observed, for 29 out of the 31 pharmacies.
119
   The FDA shared the inspection results 
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with the states, and 11 facilities were subsequently shut down after the April inspections, by their 
respective states.
120
 
Since the 2012 fungal meningitis outbreak, the somber urgent tone of discussions in both 
state and federal legislative chambers has been a catalyst for statutory action.  Since the 
outbreak, ten states have introduced or passed new legislation, or implemented new regulations 
placing additional restriction on compounding pharmacies.
121
  On the federal level, committee 
hearings have been held in both the House and the Senate, and a compromise bill was passed and 
recently signed into law to address the regulatory gaps. 
Then Representative, now Senator Edward Markey of Massachusetts, teamed up with 
Representatives Henry Waxman (D-CA), John Dingell (D-MI), Frank Pallone (D-NJ) and 
ranking member of the House Committee on Energy and Commerce Diana Degette (D-CO) to 
launch an investigation on compounding pharmacies.
122
  The legislative offices sent out 
questionnaires to the SBOP, and from the responses (from all but Rhode Island), put together a 
report published on April 15, 2013.
123
  The report indicated that only thirteen of the states could 
identify which pharmacies were performing sterile compounding.
124
  The report also concludes 
that there is no formal mechanism for SBOP to know about adverse events or other issues that 
arise from out-of-state pharmacies.
125
  States where issues with drugs arise or are discovered, do 
not consistently contact the state of origin of the drug, nor the FDA.
126
 
                                                        
120
 Examining Drug Compounding: Hearing before the H. Subcomm. On Health of the Comm. on Energy 
& Com. 113
th
 Cong. (2013) [hereinafter House May 2013 Hearing] available at 
http://energycommerce.house.gov/hearing/examining-drug-compounding (last visited Dec. 6, 2013). 
121
 STATE OF DISARRAY, supra note 17, at 12. (States include: NJ, MN, CA, MD, MA, OK, SC, UT and 
VA. Id.). 
122
 Id. 
123
 STATE OF DISARRAY, supra note 17. 
124
 Id. at 17 
125
 Id. at 21 
126
 Id. 
 22 
In addition, the House Committee on Energy and Commerce and the Senate Committee on 
Health, Education, Labor and Pensions held multiple hearings, including subcommittee hearings, 
to gather investigational testimony from the Commissioner of the FDA, and the Director of the 
FDA Center for Drug Evaluation, the Interim Commissioner of the Massachusetts Department of 
Public Health, family members of patients who died from fungal meningitis, researchers from 
the Pew Charitable Trusts, Industry Trade Association representatives, and many others.
127
  The 
many hours of questions and answers helped guide the legislators in crafting legislation, the 
result of which was passed and signed into law on November 27, 2013.
128
 
Within these hearings and discussions, there was dispute over whether the FDA actually 
required expanded authority to regulate compounding manufacturers, or whether the agency was 
too relaxed on enforcement.  The compounding industry and political conservatives argued that 
the FDA already has the requisite authority to regulate these compounding manufacturers, and 
that it is now “back-peddling” on its perceived authority in the shadow of the meningitis 
outbreak.
129
 The conservative side argues that the FDA, based on 503A in the Fifth Circuit, and 
the 2002 Compliance Policy Guide in the other states, is adequate authority to regulate 
compounding pharmacies.
130
  In addition, they argue that if the compounding manufacturer 
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resists and asserts that they are operating within their state license, the FDA can still apply for 
and obtain an administrative warrant to gain access.
131
 
The FDA and many Democrats disagreed.  The FDA requested clarity and definition of 
authority, and the registration of certain compounding manufacturers.
132
  The FDA 
Commissioner, Dr. Margaret Hamburg, repeatedly stated in the Congressional hearings, and in 
written testimony, that the FDA does not want unlimited authority over all compounders, and 
that it does not want to be in the business of regulating any pharmacy that is incidentally licensed 
to compound.
133
  Dr. Hamburg asserted that authority should remain with the states.
134
  The FDA 
Commissioner and Dr. Janet Woodcock, Director of the FDA Center for Drug evaluation and 
research, also expressed that this current process is reactionary, that it responds to problems but 
does not prevent them.
135
   Through the hours of questioning, the legislators specifically asked 
what authority the FDA thought it needed to properly prevent this type of health crisis from 
happening again.
136
   
The FDA requested clarity from Congress of the definition of non-traditional manufacturer or 
compounding manufacturer, emphasizing that this was the most central issue.
137
  Ambiguity will 
only perpetuate the pushback from facilities for ability to inspect, and result in continued 
litigation challenging FDA actions.  The FDA requested that the line between traditional 
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compounding pharmacies, and manufacturers be articulated.  Both the FDA, the industry and the 
legislators used many terms to describe these entities, calling them anything from compounding 
pharmacies, compounding manufacturers, and outsourcing facilities, which adds to the 
definitional confusion.
138
  The FDCA and FDAMA draw the line that a compounding pharmacy 
will not be subject to New Drug Application requirements if they produce a limited amount of 
the compounded drug, but the FDA asked Congress to specify whether that means “10 units, 
1,000 units or 10,000 units” etc.139  This is vital because even if these companies are operating 
outside the scope of their state compounding license, the FDA authority over traditional 
manufacturers has different scope and applicability than what is needed for compounding 
manufacturers.
140
 
 Another concern repeatedly expressed by the FDA was that if a doctor, clinic or 
pharmacy discovers a problem in one state with a drug that came from out-of-state, the SBOP 
where the problem was found cannot go out and investigate and regulate the pharmacy in a 
foreign state.
141
  They must contact the home SBOP and hope that they respond.
142
  To remedy 
this potential area for problems, the FDA expressed a desire for a formal communication 
procedure both between states and between the states and the FDA.
143
   
Another issue expressed by the FDA is that the agency has no metrics on how many of these 
compounding manufacturers exist across the United States, with estimates varying between 
7,500
144
 and 23,000.
145
  The FDA asked for legislation to either require that pharmacies that 
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compound high volumes of sterile products for shipment to other states, register with the FDA, 
or instruct the FDA to promulgate a rule regarding registration.
146
  This way the FDA would 
know where these facilities are located, what they are producing, and to what locations they are 
distributing.
147
  This registration process was suggested to require the companies to pay a fee, to 
help cover the additional administrative costs to the FDA.
148
  Adding a penalty, or monetary fine, 
for not registering would also provide an incentive for companies to comply.   This knowledge of 
where these entities are operating, would be followed-up by FDA ability to inspect facilities, as 
well as documents and records (to be able to determine where they were shipping and when, 
which batches to inspect), the ability to take and test samples from the facilities, the ability to 
seize adulterated drugs, to issue penalties and even close down facilities found in violation of the 
FDCA.   
V. Crafting New Legislation to Prevent Another Outbreak 
After hours of hearings, pages of testimony, and requests for comments and input from both 
the government agencies and the compounding industry, Congress decided that legislation was 
necessary to prevent another outbreak.  Though several bills were drafted in both the House and 
Senate, one bill emerged from Committee as the compromise between the House and the Senate.  
This bill H.R.3204/S.8027, was recently signed into law, titled the “Drug Quality and Security 
Act.
149
 
A. Proposed Federal statutory changes  
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A flurry of federal legislation has been introduced in response to the meningitis outbreak, and 
the subsequent congressional hearings.  There were several proposals in the House, and one from 
the Senate Committee on Health, Education, Labor and Pensions.
150
  On September 28, 2013, on 
the eve of the shutdown of the Federal Government, the House, after a short, and mostly one-
sided debate passed H.R. 3204 on a voice vote.
151
  This bill was sponsored by the Chair of the 
House Committee on Energy and Commerce, Republican Representative Fred Upton of 
Michigan, and was cosponsored by six Democrats and four Republicans.
152
  This bill was a 
compromise bill between the House and Senate Committees that were working on similar drafts, 
and passed in the Senate by a voice vote on November 18, 2013.
153
  It was signed into law by the 
President on November 27, 2013.
154
  It is also worth noting that this bill was supported by many 
relevant organizations, including PhRMA, PharMEDium
155
, and the National Community 
Pharmacists Association.
156
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The Drug Quality and Security Act (hereinafter “the Act”), began as two bills with different 
agendas and so, has two parts.  The first section, Title I, amends the FDAMA Section 503, and 
creates an exception to certain FDA regulations for those entities, which it labels “outsourcing 
facilities”, that comply with eleven requirements and voluntarily register with the FDA.157  Title 
II of the Act makes changes to drug distribution and supply chain tracing laws, and is not 
pertinent to the change in regulatory authority over outsourcing facilities, therefore, will not be 
discussed in this analysis.
158
 
This Act eliminates the controversial advertising provision in section 503A of the FDAMA, 
and amends the section intended to apply to traditional compounding or retail pharmacies. The 
bill re-names the current 503B, to be 503C, and inserts a new section 503B, intended to 
encompass compounding manufacturers or “outsource facilities”.159  The new 503B 
acknowledges that outsourcing facilities are manufacturers, and will be regulated as such under 
the FDCA, but carves out an exemption for those facilities that operate in accordance with 
503B.
160
   The eleven requirements for exempt outsource facilities laid forth in 503B are: 
1) Voluntary registration with FDA as an “outsourcing facility”. 
2) The drug compounded does not use “bulk drug substances”, unless done in 
compliance with the USP monograph,  or there is a shortage for the drug. 
3) Any other ingredients, besides bulk substances, are compounded in compliance with 
the USP. 
4) The outsource facility does not compound drugs or components withdrawn from the 
market because it is unsafe or not effective. 
5) The outsource facility cannot compound what are “essentially copies” of an FDA 
approved drug. 
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6) If outsource facility compound drugs that are “demonstrably difficult” to produce, as 
identified by the FDA, they must follow additional safeguards during production. 
7) If the drug has been compounded from a drug that is subject to a risk evaluation and 
mitigation strategy (identified as more dangerous in some respect), then it must 
follow specific safety controls determined by the FDA. 
8) The outsourcing facility is prohibited from wholesaling. 
9) The outsourcing must pay fees to the FDA. 
10) It must label the drug with contact information of the outsourcing facility, specific 
information about the batch and lot number of the drug, the drug name, and “this is a 
compounded drug”, and “not for resale”, among other things. 
11) In addition to registering with the FDA, the outsourcing facility must make its facility 
and records “available” for regular risk-based inspections by the FDA, report all 
adverse events.
161
   
 
If the eleven requirements of 503B are met, outsourcing facilities are expressly exempted from 
the NDA application process, and certain labeling requirements.
162
   
The Act requires outsourcing facilities to pay a $15,000 annual fee to register with the FDA, 
adjusted for inflation and for small businesses (to be defined by the FDA).
163
  Outsourcing 
facilities would be subject to current good manufacturing practice requirements of the FDCA, 
and those registered facilities would not be required to be a licensed pharmacy within the state 
they operate.
164
  There is careful attention to try to prevent the mistakes of the past; including 
adding a provision specifically stating that if any section of this law is found unconstitutional, it 
is severable and the rest will stand.
165
  The FDA is required to establish a risk-based inspection 
system for outsourcing facilities, taking into account various factors including, the compliance 
history of the facility, any recalls linked to the facility, whether it has registered (implying that 
unregistered facilities are still subject to inspection authority).
166
  In Section 105 of the Act, 
“Enhanced Communication”, SBOPs are required to alert the FDA when they take action against 
compounding pharmacies operating outside of 503A, with warning letters, suspension of license, 
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or recall of drugs.
167
  The FDA would be required to contact SBOP if they receive an alert from a 
state, or if the FDA itself makes a determination based on a risk-based inspection that a 
pharmacy is operating outside of 503A.
168
    
B. Analyzing the strengths and weaknesses of the Act 
Some argue, regardless of whether they are called “compounding manufacturers” or 
“outsourcing facilities”, that the FDA and the States currently have the adequate authority to 
regulate non-traditional compounding facilities.
169
  This argument is unconvincing, as the legal 
framework of the past was insufficient.  The new legislation shows promise to address many of 
the concerns raised by the FDA, however it leaves some questions to be answered. 
The first obvious disconnect from what the FDA requested, and the language of the Act, is 
that 503A is amended only to eliminate the unconstitutional advertising provision.  Sec. 
503A(a)(2)(A) defines that a licensed pharmacist or licensed physician can compound without a 
valid prescription “in limited quantities”, without defining “limited quantity”.170   This leaves the 
same definitional loophole open for facilities to claim that they are exempt from the FDCA new 
drug approval and labeling requirements, operating under a state pharmacy license, and not 
subject to FDA authority.  The same lawsuits and industry resistance to inspections are very 
likely to continue.  In addition, though the new 503B includes a definition of “compounding”, 
503A does not.  The Act’s silence may give the FDA the ability to adopt a reasonable, but 
perhaps different definition that applies to traditional compounding.
171
 
The next important difference is that registration as an “outsourcing facility” is voluntary and 
left to the discretion of the compounding facility.  This seemingly puts the onus on the hospitals, 
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clinics, and healthcare providers to only purchase drugs from registered outsourcing facilities, or 
those properly licensed by the state.  Registered outsourcing facilities with higher operating 
costs, including FDA fees, will have to compete with unregistered facilities.  Rather than leaving 
it up to the outsourcing facility, legislators should have written in specific criteria, such as sterile 
drug production, across state lines, and above a certain number of units, i.e. 1,000 units per 
month or more, in volume.   In Sec. 503B(d)(4)(a) of the Act, an “outsourcing facility” is defined 
as; “(i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an 
outsourcing facility; and (iii) complies with all of the requirements of this section.”172  This 
leaves open the question as to whether the Act applies to facilities who produce non-sterile 
products, and if not, whether the FDA should leave regulation of non-sterile facilities entirely to 
the state.  The Act does not address the compounding or repackaging of biological drugs, or 
biologics, and whether they also may be outsourcing facilities.  The FDA regulates both human 
and veterinary drug manufacturing, but H.R. 3204 does not address the compounding of 
medicines for animal use, so it is unclear how those facilities may be affected. 
The FDA is required by the Act to establish a list of those bulk drugs “for which there is a 
clinical need”, or are in a drug shortage.173  The drugs included on this list are not exempt from 
regulation, but are subject to different restrictions, due to the emergency need to create more 
supply.
174
  The Act does not address how outsourcing facilities, hospitals or clinics may request 
that drugs are added to that list, or how the FDA might process a request of such nature.
175
  The 
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Act did not set forth how these requirements will be initiated or phased in, which means that it 
would take effect immediately upon its passage.  This may have the effect of halting compound 
drug production at facilities that are attempting to get into compliance.   
Commissioner Hamburg released a statement of mild disappointment after the Act became 
law.
176
  The Commissioner acknowledged that she was “pleased” with its passage, and that it is a 
“good step” toward “stronger drug quality and safety laws”, but that all of authority and clarity 
she asked for was not included.
177
 
Almost immediately after the Act was signed into law, the FDA issued two draft guidance 
documents on how the FDA interprets each section of the Act.
178
  The FDA also issued three 
Notice of Proposed Rules for the list of bulk substances to apply to each section, and requested 
nominations for additions to those lists.
179
  The draft guidance for Sec. 503B gives outsource 
facilities instruction on how to register with the FDA if they meet the requirements, when they 
must register, what information is required and what fees will be assessed.
180
  The draft guidance 
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for pharmacy compounding under the new Sec. 503A restates the requirements for exemption 
from enhanced FDA reporting and advertising restrictions, and emphasizes that the FDA will 
exercise enforcement authority over those entities that operate outside that exemption. 
181
  The 
guidance states that the FDA will use a risk-based approach to discovering and investigating 
compounding pharmacies or outsource facilities to catch violations.
182
 However, these guidance 
documents leave the same loophole open for compounding facilities to decline registration with 
the FDA, claim compliance with state pharmacy laws, and potentially avoid heightened 
regulatory scrutiny.  If compounding manufacturers, or outsource facilities, collectively decide 
not to register with the FDA, the Act leaves open many of the same concerns addressed above in 
Part IV (B). 
Under the new law, forces beyond government regulation could also drive patient safety.  
With the new Act responsibility for ensuring safe drugs are administered to patients also falls to 
the clinics and hospitals that purchase these compound medications.  If these vendors all decide 
to only purchase from outsource facilities that are registered with the FDA, then it may be seen 
as an indication of quality and become the industry standard.   
 The intended effect of the Act is to ensure more uniform nationwide compliance with safety 
procedures in outsourcing facilities, especially those that compound sterile preparations.  
Consistent and rigorous compliance will lead to greater patient safety. The FDA is able to ensure 
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compliance in the big pharmaceutical manufacturing facilities, with a proverbial carrot and stick 
approach.  The Department of Justice offers an incentive to whistleblowers (relators) who report 
violations under the False Claims Act.
183
  In those cases, if a relator reports information that 
results in a judgment the relator can receive up to thirty percent of the penalty assessed.
184
  The 
big pharmaceutical companies do business in the millions or billions of dollars, and therefore 
have a lot to loose if they get hit with large civil and criminal monetary penalties for violations.  
The FDA should ensure that it uses these same incentives and penalties against outsource 
facilities, or compounding manufacturers who operate outside the law.  This type of cash 
incentive should also be applied to whistleblowers that report compounding safety and quality 
violations, and hand out heavy monetary penalties to bad actors.  The FDA should not hesitate to 
use individual exclusion from the Medicare/Medicaid reimbursement system, to prevent people 
like Barry Cadden, the CEO at NECC, or his partners, from reorganizing under a different 
company name after one has its license revoked for violations.    
B. Conclusion 
As this paper has presented, the former status quo ensuring the safety and quality of 
compounded drugs, especially sterile products, creates enforcement confusion and has resulted in 
contaminated drugs.  The combination of FDAMA §503A in the Fifth Circuit, and the 2002 CPG 
everywhere else promoted a reactionary enforcement environment rather than a proactive 
regulation environment.  The states and the FDA need a proactive and aggressive approach to 
ensure sterile products are produced in facilities that follow current GMPs, tailored to these 
businesses and their safety issues.  Congress has acted to clarify the responsibilities and duties of 
both the FDA and the states, but it remains to be seen if this law will be adequate.  In addition to 
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the jurisdictional clarity, both state and federal enforcement authorities must take action and 
continue to keep the pressure on compounding facilities with risk-based inspections.  The FDA 
currently oversees approximately 5,600 manufacturers,
185
 and with the fiscal financial limits 
under sequestration it may be difficult, but it is necessary to prevent future public health crises. 
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